At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Nicotine (5 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Nicotine on Chronic Pelvic Pain
In Brief
A Phase 4 clinical trial evaluating Placebo, Nicotine (5 mg), and 1 other intervention for Pelvic Pain. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to test whether transdermal nicotine reduces pain among women with chronic pelvic pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPelvic Pain
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
First PostedFeb 2007
Primary CompletionJun 2008
TodayJul 2026
First PostedFeb 27, 2007
Enrollment StartFeb 1, 2004
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.3 years ago
Interventions
Placebodrug
Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
Nicotine (5 mg)drug
Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
Nicotine (10 mg)drug
Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.